Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

I am searching for a
Reset Form
Christopher D. Watt, MD, PhD

Christopher D. Watt, MD, PhD Physician

Associate Director, Molecular Pathology Laboratory Associate Professor of Clinical Pathology and Laboratory Medicine

Dr. Watt is employed by Penn Medicine.

No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients in a medical practice setting.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.

Clinical Specialties


  • Pathology and Laboratory Medicine

Programs & Centers:

  • Precision and Computational Diagnostic Services

Board Certification:

  • Pathology - Clinical Pathology, 2008
  • Pathology - Molecular Genetic Pathology, 2009

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American Medical Association, Member, National American Society for Clinical Pathology, Fellow Member, International Association for Molecular Pathology, Associate Member, International College of American Pathologists, Fellow Member, International

Hospital Affiliation

Dr. Watt is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.


Selected Publications:

NelsonW, Bagley S, Watt CD, and Nasrallah M: An institutional experience with pyrosequencing for MGMT promoter methylation analysis. Modern Pathology 32 (supplement 2): 29,2019.

Belman J, Gentile C, Lake JI, Roth JJ and Watt CD: Optimizing RNA extraction to facilitate BCR/ABL1 quantitative testing. The Journal of Molecular Diagnostics 20 (6): 1031,2018.

Bhattacharyya S, Castro-Echeverry E, Kelly LM, Burnes CL, Gentile C, Roy S, Nikiforova M, Watt CD and Aggarwal N: Standardization of FLT3-ITD mutation allelic ratio reporting in the clinical laboratory setting. The Journal of Molecular Diagnostics 20 (6): 920,2018.

Rathore S, Bakas S, Nasrallah MP, Bagley SJ, Akbari H, Ha SM, Mamourian EC, Watt CD, and Davatzikos C: Non-invasive determination of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status in glioblastoma (GBM) using magnetic resonance imaging (MRI). Journal of Clinical Oncology 36 (suppl): 2018.

McMahon CM, Ferng TT, Canaani J, Rea B, Sargent RL, Morrissette JJD, Lieberman DB, Watt CD, Durruthy-Durruthy R, Pellegrino M, Eastburn DJ, Wang ES, Shah NP, Carroll M, Smith CC, and Perl AE: Ras mutations are the dominant mechanism of secondary resistance to gilteritinib therapy for relapsed/refractory FLT3-mutated AML. EHA Learning Center : 2018.

McMahon CM, Canaani J, Rea B, Sargent RL, Morrissette JJD, Lieberman DB, Watt CD, Schwartz GW, Faryabi RB, Ferng TT, Shah NP, Smith CC, Caroll M, and Perl AE: Mechanisms of acquired resistance to Gilteritinib therapy in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood 130 (s1): 295,2017.

Hatem J, Schrank-Hacker AM, Watt CD, Morrissette JJ, Rubin AI, Kim EJ, Nasta SD, Wasik MA, Bogusz AM.: Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report. Diagnostic Pathology 11 : 137,2016.

Surrey LF, Smith JR, Lubin D, Van Deerlin V, Watt CD: Analytic Approach for Complete and Mixed Engraftment Analysis using Commercial Software. The Journal of Molecular Diagnostics 18 (6): 1030,2016.

Press RD, Watt CD, Cai L, Van Deerlin VM, Roth JJ, Gentile C, Loren A, and Eickelberg G: BCR-ABL1 molecular responses at 12-18 months predict long-term event-free survival in patients with tyrosine kinase inhibitor (TKI)-treated chronic myelogenous leukemia (CML). The Journal of Molecular Diagnostics 18 (6): 964,2016.

Roth JJ, Windon AL, Strubinger J, Carlin A, Gentile C, Watt CD, McGrath CM, Van Deerlin VM: Improvements in workflow after verification and implementation of the cobas® HPV Test. The Journal of Molecular Diagnostics 18 (6): 970,2016.

Academic Contact Info

Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
3400 Spruce Street

Philadelphia, PA 19104
Patient appointments: 800-789-7366 (PENN)